Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH61ZB)

• Drug Name: Cimetidine Drug Info
• Synonyms: Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine

Indication

Disease Entry	ICD 11	Status	REF
Acid-reflux disorder	DA22	Approved	[1]
Gastric ulcer	DA60	Approved	[2]
Gastrinoma	2C10.1	Approved	[2]

• Therapeutic Class: Antiulcer Agents
• Cross-matching ID:
  PubChem CID: 2756
  ChEBI ID: CHEBI:3699
  CAS Number: CAS 51481-61-9
  TTD Drug ID: DMH61ZB
  VARIDT Drug ID: DR00037
  INTEDE Drug ID: DR2272
  ACDINA Drug ID: D00130

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine H2 receptor (H2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[16]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[3]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[17]
Betazole	DMUFGAY	Gastric secretory disorder	DD90	Approved	[18]
Ebrotidine	DMV5KR3	Duodenal ulcer	DA63	Withdrawn from market	[19]
Pibutidine	DMXSTRM	Ulcerative colitis	DD71	Discontinued in Phase 3	[20]
Osutidine	DMN7TL8	Duodenal ulcer	DA63	Discontinued in Phase 3	[21]
KU-1257	DMZMFX6	Duodenal ulcer	DA63	Discontinued in Phase 3	[22]
Lavoltidine	DMTY5VE	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[23]
IGN-2098	DMU4N1O	Duodenal ulcer	DA63	Discontinued in Phase 2	[24]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[25]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[26]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[9]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[27]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[9]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[9]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[28]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[9]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[29]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[31]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[32]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[33]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[34]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[35]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[36]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[38]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]

Drug(s) Transported By Organic cation transporter 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[41]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[42]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[43]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[44]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[45]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[46]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[47]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[45]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[48]

Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[5]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[49]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[5]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[50]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[5]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[5]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[51]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[52]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[53]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[54]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[72]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[73]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[74]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[79]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[74]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[80]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[40]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[55]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[56]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[57]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[25]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[58]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[59]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[60]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[61]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[45]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[62]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[63]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[64]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[65]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[66]
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[67]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[68]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[69]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[70]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[71]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[96]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[97]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[98]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[65]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[48]
Cefdinir	DMJ7A0H	Bacterial infection	1A00-1C4Z	Approved	[99]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[99]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[100]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[101]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[102]

Drug(s) Transported By Multidrug and toxin extrusion protein 2 (SLC47A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[5]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[5]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[5]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[5]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[5]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[52]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[53]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[5]
N-methylpyridinium	DMVUKEW	N. A.	N. A.	Preclinical	[5]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[5]

Drug(s) Affected By Solute carrier family 22 member 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[81]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[82]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[48]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[83]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[48]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[84]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[85]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[86]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[87]
Indomethacin	DMSC4A7	Bursitis		Approved	[84]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[88]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[88]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[89]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[13]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[90]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[91]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[92]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[93]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[94]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[95]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[103]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[104]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[105]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[106]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[107]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[108]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[109]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[110]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[111]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[112]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[112]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[112]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[113]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[114]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[115]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[116]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[117]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[118]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[13]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[120]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[121]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[122]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[123]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[124]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[113]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[107]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[125]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[126]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[104]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[107]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[106]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[113]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[128]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[107]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[129]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[106]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[107]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[130]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[130]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[131]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[132]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[133]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[130]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[130]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[130]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[134]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[135]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[136]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[137]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[138]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[139]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[140]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[141]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[142]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[143]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[144]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[145]

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[146]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[147]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[13]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[148]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[149]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[150]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[151]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[13]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[153]

Drug(s) Affected By Glutathione S-transferase P (GSTP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[154]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[155]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[156]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[156]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[157]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[158]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[159]
Selenium	DM25CGV	N. A.	N. A.	Approved	[160]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[161]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[162]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[163]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[164]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[165]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[166]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[167]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[168]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[169]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[170]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[172]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[173]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[175]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[176]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[179]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[180]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[12]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[181]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[134]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[182]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[183]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[184]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[185]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[186]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[12]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[187]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[188]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]

Drug(s) Affected By Apoptotic protease-activating factor 1 (APAF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[191]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[195]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[196]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[197]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[198]

Drug(s) Affected By Follitropin subunit beta (FSHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[199]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[200]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[201]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[202]
Cetrorelix	DMFD9Q6	Ovarian stimulation	LB45.1	Approved	[203]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[204]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[205]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[206]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[207]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[208]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[209]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[210]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[211]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[212]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[213]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[214]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[215]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[216]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[217]

Drug(s) Affected By Gastrin (GAST)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[218]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Terbutaline	DMD4381	Asthma	CA23	Approved	[219]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[220]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[207]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[218]
Lansoprazole	DMXYLQ3	Gastric ulcer	DA60	Approved	[221]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[222]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[13]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[223]

Drug(s) Affected By Interferon gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[224]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[225]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[226]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[227]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[228]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[229]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[230]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[231]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[232]

Drug(s) Affected By Intercellular adhesion molecule 1 (ICAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[233]
Dicloxacillin	DM8EU0Z	Bacterial infection	1A00-1C4Z	Approved	[233]
Ergonovine	DM0VEC1	Postpartum haemorrhage	JA43	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[234]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[235]
Mizolastine	DM1FDN8	Allergic rhinitis	CA08.0	Approved	[236]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[237]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[238]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[239]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[240]

Drug(s) Affected By Monocyte differentiation antigen CD14 (CD14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[241]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[242]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[243]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[244]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[245]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[246]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[247]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[248]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[249]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[250]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[251]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[252]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[253]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[254]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[255]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[256]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[257]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[258]

Drug(s) Affected By Integrin alpha-4 (ITGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[259]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[259]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[260]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[261]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[262]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[263]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[259]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[264]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[265]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[266]

Drug(s) Affected By P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[267]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[268]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[269]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[270]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[271]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[272]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[273]
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[274]

Drug(s) Affected By Integrin alpha-X (ITGAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[275]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[276]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[246]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[277]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[278]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[279]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[280]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[280]
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[281]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[282]

Drug(s) Affected By Caspase-1 (CASP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[189]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[283]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[284]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[285]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[239]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[191]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[286]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[287]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[288]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[289]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[290]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[291]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[292]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[293]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[294]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[295]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[296]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[297]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[298]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[299]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[300]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[241]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[301]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[302]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[303]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[303]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[304]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[305]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[306]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[307]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[308]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[254]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[256]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[309]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[310]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[311]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[312]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[313]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[314]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[250]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[299]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[254]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[255]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[315]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[309]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[316]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[159]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[317]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[318]

Drug(s) Affected By Prolow-density lipoprotein receptor-related protein 1 (LRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[319]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[245]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[198]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[320]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[321]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[322]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[323]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[324]

Drug(s) Affected By Interleukin-18 (IL18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[189]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[159]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[325]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[289]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[326]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[327]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[328]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[327]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[329]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[330]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[331]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[189]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[332]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[333]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[311]
Selenium	DM25CGV	N. A.	N. A.	Approved	[160]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[313]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]

Drug(s) Affected By L-lactate dehydrogenase B chain (LDHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[319]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[334]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[335]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[336]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[326]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[337]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[198]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[334]

Drug(s) Affected By L-lactate dehydrogenase C chain (LDHC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[180]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[338]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[339]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[262]

Drug(s) Affected By Parathyroid hormone (PTH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[340]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[341]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[342]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[343]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[344]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[345]
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[346]
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[347]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[13]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[348]

Drug(s) Affected By Calcineurin subunit B type 1 (PPP3R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[198]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[349]
Bortezomib	DMNO38U	Leukemia		Approved	[350]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[207]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[351]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[352]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[13]
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[13]
Tacrolimus	DMZ7XNQ	Graft-versus-host disease	4B24	Approved	[13]

Drug(s) Affected By Solute carrier family 22 member 6 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[97]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[84]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[102]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[84]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[84]
Succinic acid	DMDWICP	Malnutrition	5B50-5B71	Approved	[353]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[84]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[354]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[84]

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[84]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[355]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[94]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[356]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[356]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[356]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[356]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[356]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[356]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[48]

Drug(s) Affected By Bifunctional epoxide hydrolase 2 (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[319]
Selenium	DM25CGV	N. A.	N. A.	Approved	[160]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[141]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[357]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[358]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[359]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[359]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[79]

Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[360]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[360]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[360]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[361]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[362]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[87]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[363]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[364]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Antagonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[4]
Multidrug and toxin extrusion protein 2 (SLC47A2)	DT3TX4H	S47A2_HUMAN	Substrate	[5]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[5]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[7]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[10]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[10]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Gene/Protein Processing	[11]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[12]
Bifunctional epoxide hydrolase 2 (EPHX2)	OTPTRCNW	HYES_HUMAN	Drug Response	[13]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Regulation of Drug Effects	[14]
Calcineurin subunit B type 1 (PPP3R1)	OTGQNFJQ	CANB1_HUMAN	Drug Response	[13]
Caspase-1 (CASP1)	OTZ3YQFU	CASP1_HUMAN	Gene/Protein Processing	[15]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[11]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1231).
• [2] Cimetidine FDA Label
• [3] Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
• [4] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [5] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
• [6] Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
• [7] Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
• [8] Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
• [9] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [10] Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 2010 Mar;23(3):693-700. doi: 10.3892/or_00000686.
• [11] Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8.
• [12] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005 Jan;312(1):144-52. doi: 10.1124/jpet.104.073916. Epub 2004 Sep 13.
• [15] Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. doi: 10.1124/mol.106.025890. Epub 2006 May 24.
• [16] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [17] Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
• [18] Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
• [19] Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
• [20] Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
• [21] Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
• [22] Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
• [23] New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
• [24] Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
• [25] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [26] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [27] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [28] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [29] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [30] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [31] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [32] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [33] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [34] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [35] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [36] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [37] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [38] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [39] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [40] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [41] Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
• [42] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
• [43] Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
• [44] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [45] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [46] The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
• [47] Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
• [48] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [49] Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
• [50] Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
• [51] Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
• [52] Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
• [53] FDA Drug Development and Drug Interactions
• [54] Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
• [55] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [56] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [57] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [58] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [59] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [60] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [61] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [62] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [63] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [64] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [65] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [66] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [67] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [68] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [69] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [70] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [71] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [72] Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
• [73] Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
• [74] Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74. doi: 10.1124/dmd.106.010876. Epub 2006 Aug 23.
• [75] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [76] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [77] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [78] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [79] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [80] Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol In Vitro. 2017 Sep;43:87-91. doi: 10.1016/j.tiv.2017.06.007. Epub 2017 Jun 9.
• [81] Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
• [82] Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
• [83] Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
• [84] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [85] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [86] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [87] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [88] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [89] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [90] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [91] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [92] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [93] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [94] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [95] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [96] Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2023 Jan 1;483:153387. doi: 10.1016/j.tox.2022.153387. Epub 2022 Dec 1.
• [97] P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
• [98] Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 2015 Feb;29(1):251-8. doi: 10.1016/j.tiv.2014.10.019.
• [99] Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
• [100] Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
• [101] Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
• [102] Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
• [103] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [104] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [105] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [106] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [107] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [108] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [109] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [110] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [111] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [112] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [113] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [114] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [115] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [116] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [117] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [118] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [119] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [120] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [121] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [122] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [123] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [124] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [125] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [126] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [127] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [128] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [129] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [130] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [131] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [132] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [133] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [134] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [135] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [136] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [137] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [138] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [139] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [140] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [141] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [142] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [143] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [144] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [145] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [146] Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
• [147] Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
• [148] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [149] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [150] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [151] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [152] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [153] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [154] Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
• [155] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [156] The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
• [157] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [158] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [159] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [160] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [161] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [162] Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12.
• [163] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [164] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [165] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [166] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [167] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [168] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [169] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [170] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [171] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [172] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [173] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [174] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [175] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [176] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [177] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [178] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [179] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [180] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [181] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [182] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [183] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [184] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [185] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [186] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [187] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [188] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [189] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [190] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [191] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [192] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [193] Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
• [194] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [195] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [196] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [197] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [198] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [199] Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
• [200] Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
• [201] [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
• [202] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [203] Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp Clin Endocrinol Diabetes. 1999;107(1):63-9. doi: 10.1055/s-0029-1212075.
• [204] Aromatase inhibition, testosterone, and seizures. Epilepsy Behav. 2004 Apr;5(2):260-3. doi: 10.1016/j.yebeh.2003.12.001.
• [205] Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009 Jan;34(1):129-39. doi: 10.1016/j.psyneuen.2008.08.015. Epub 2008 Oct 5.
• [206] Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918-22. doi: 10.1210/jcem.85.5.6527.
• [207] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [208] Chronic naltrexone treatment induces desensitization of the luteinizing hormone pulse generator for opioid blockade in hyperprolactinemic patients. J Clin Endocrinol Metab. 1995 May;80(5):1739-42. doi: 10.1210/jcem.80.5.7745028.
• [209] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [210] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [211] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [212] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [213] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [214] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [215] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [216] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [217] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [218] Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
• [219] L-type calcium channels regulate gastrin release from human antral G cells. Am J Physiol. 1997 Aug;273(2 Pt 1):G281-8. doi: 10.1152/ajpgi.1997.273.2.G281.
• [220] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [221] Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion. 1995;56(2):137-44. doi: 10.1159/000201233.
• [222] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [223] Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013 Feb;27(1):37-48. doi: 10.1007/s10557-012-6427-8.
• [224] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [225] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [226] Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007 Jul;75(1):36-42. doi: 10.1016/j.antiviral.2006.11.008. Epub 2006 Dec 13.
• [227] Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
• [228] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [229] The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim Biophys Acta. 2002 Dec 16;1593(1):29-36. doi: 10.1016/s0167-4889(02)00328-2.
• [230] [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
• [231] Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. Chemotherapy. 1998 May-Jun;44(3):174-80. doi: 10.1159/000007112.
• [232] Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chem Res Toxicol. 2016 Nov 21;29(11):1793-1795. doi: 10.1021/acs.chemrestox.6b00393. Epub 2016 Nov 9.
• [233] Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother. 2004 Feb;53(2):174-9. doi: 10.1093/jac/dkh056. Epub 2004 Jan 16.
• [234] Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
• [235] The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005 Jul-Aug;26(4):292-8.
• [236] Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. doi: 10.1034/j.1398-9995.2000.00803.x.
• [237] Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
• [238] Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy. Rom J Gastroenterol. 2003 Jun;12(2):91-5.
• [239] Some non-sensitizers upregulate CD54 expression by activation of the NLRP3 inflammasome in THP-1 cells. J Toxicol Sci. 2019;44(3):213-224. doi: 10.2131/jts.44.213.
• [240] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [241] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [242] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [243] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [244] Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients. Exp Mol Med. 2003 Oct 31;35(5):454-9. doi: 10.1038/emm.2003.59.
• [245] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [246] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [247] Histamine downregulates CD14 expression via H2 receptors on human monocytes. Clin Immunol. 2003 Sep;108(3):274-81. doi: 10.1016/s1521-6616(03)00140-2.
• [248] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [249] The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids. Nephrol Dial Transplant. 2001 Feb;16(2):246-52. doi: 10.1093/ndt/16.2.246.
• [250] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [251] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [252] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [253] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [254] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [255] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [256] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [257] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [258] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [259] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [260] Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
• [261] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [262] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [263] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [264] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [265] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [266] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [267] Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
• [268] Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl). 2000 Mar;113(3):236-40.
• [269] Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
• [270] Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36(7):552-7. doi: 10.1080/07853890410017386.
• [271] Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
• [272] Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis. 2008 Jul;199(1):55-64. doi: 10.1016/j.atherosclerosis.2007.10.038. Epub 2008 Feb 21.
• [273] Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.
• [274] A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost. 1999 Oct;82(4):1255-9.
• [275] Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Pediatr Blood Cancer. 2006 Apr;46(4):506-11. doi: 10.1002/pbc.20392.
• [276] Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J Pharmacol Exp Ther. 2006 Jan;316(1):304-14. doi: 10.1124/jpet.105.092874. Epub 2005 Sep 20.
• [277] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [278] Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
• [279] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [280] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [281] Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 1997 Jan;63(1):105-11. doi: 10.1016/s0003-4975(96)00743-6.
• [282] Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000 Mar;6(3):825-8.
• [283] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [284] Cannabidiol Protects Human Skin Keratinocytes from Hydrogen-Peroxide-Induced Oxidative Stress via Modulation of the Caspase-1-IL-1 Axis. J Nat Prod. 2021 May 28;84(5):1563-1572. doi: 10.1021/acs.jnatprod.1c00083. Epub 2021 May 6.
• [285] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [286] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [287] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [288] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [289] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [290] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [291] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [292] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [293] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [294] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [295] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [296] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [297] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [298] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [299] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [300] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [301] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [302] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [303] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [304] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [305] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [306] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [307] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [308] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [309] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [310] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [311] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [312] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [313] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [314] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [315] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [316] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [317] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [318] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [319] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [320] The effect of rosiglitazone on LRP1 expression and amyloid uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012 Feb;15(1):135-42. doi: 10.1017/S1461145711001611. Epub 2011 Nov 1.
• [321] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [322] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [323] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [324] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [325] AS3MT facilitates NLRP3 inflammasome activation by m(6)A modification during arsenic-induced hepatic insulin resistance. Cell Biol Toxicol. 2023 Oct;39(5):2165-2181. doi: 10.1007/s10565-022-09703-7. Epub 2022 Feb 28.
• [326] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [327] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [328] Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells. Chem Biol Interact. 2021 May 1;340:109434. doi: 10.1016/j.cbi.2021.109434. Epub 2021 Mar 6.
• [329] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [330] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [331] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [332] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [333] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [334] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [335] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [336] Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. Proteomics. 2008 Apr;8(8):1595-607. doi: 10.1002/pmic.200700556.
• [337] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [338] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [339] Linking site-specific loss of histone acetylation to repression of gene expression by the mycotoxin ochratoxin A. Arch Toxicol. 2018 Feb;92(2):995-1014.
• [340] Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron. 1994;67(1):48-53. doi: 10.1159/000187887.
• [341] Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis. 2006 Nov;48(5):832-7. doi: 10.1053/j.ajkd.2006.07.019.
• [342] Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010 Dec 13;5(12):e15235. doi: 10.1371/journal.pone.0015235.
• [343] Phenytoin induced vitamin D deficiency presenting as proximal muscle weakness. Indian Pediatr. 2010 Jul;47(7):624-5. doi: 10.1007/s13312-010-0121-3.
• [344] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [345] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [346] Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008 May;3(3):658-64. doi: 10.2215/CJN.04981107. Epub 2008 Feb 6.
• [347] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr;63(4):1483-90. doi: 10.1046/j.1523-1755.2003.00878.x.
• [348] A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer. 1998 Jul;78(1):6-13. doi: 10.1038/bjc.1998.434.
• [349] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [350] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [351] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [352] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [353] Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
• [354] Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
• [355] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [356] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [357] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [358] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [359] Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
• [360] Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
• [361] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [362] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [363] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [364] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.